Results 301 to 310 of about 121,769 (336)

Anti-inflammatory Potential of GSK-3 Inhibitors

Current Drug Targets, 2021
Glycogen synthase kinase-3 (GSK-3) is a protein kinase containing threonine or serine amino acid residues. GSK-3 was first discovered in 1980 as a regulatory protein kinase, Glycogen synthase (GS) enzyme, which is responsible for the conversion of glycogen from glucose with the help of uridine diphosphate glucose (UDP-Glu) residue.
Chandi C. Kandar, Debanjan Sen, Arindam Maity   +2 more
openaire   +2 more sources

GSK-3 Inhibitors: Discoveries and Developments

Current Medicinal Chemistry, 2004
Glycogen synthase kinase 3 (GSK-3) in the 21(st) century emerged as one of the most attractive therapeutic target for the development of selective inhibitors as new promising drugs for unmet pathologies including Alzheimer's disease, stroke, bipolar disorders, chronic inflammatory processes, cancer and diabetes type II.
M, Alonso, A, Martinez
openaire   +2 more sources

Schizophrenia as a GSK-3 dysregulation disorder

Trends in Neurosciences, 2007
Converging evidence suggests that the regulation of glycogen synthase kinase 3 (GSK-3) might be important in schizophrenia. Atypical and typical antipsychotic drugs alter GSK-3 activity, as do drugs that induce psychosis. GSK-3 regulatory pathways are altered in schizophrenia, and many of the genes associated with schizophrenia directly or indirectly ...
Lovestone, S, Killick, R, Di Forti, M, Murray, R   +3 more
openaire   +3 more sources

Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
A series of [1-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]arylhydrazones were discovered as novel inhibitors glycogen synthase kinase-3 (GSK-3). Based on initial modeling a detailed SAR was constructed. Modification of the interior binding aryl ring (Ar(1)) determined this to be a tight binding region with little room for modification. As predicted from the
Andrew J, Peat, Joyce A, Boucheron, Scott H, Dickerson, Dulce, Garrido, Wendy, Mills, Jennifer, Peckham, Frank, Preugschat, Terrence, Smalley, Stephanie L, Schweiker, Jayme R, Wilson, Tony Y, Wang, Huiqiang Q, Zhou, Stephen A, Thomson   +12 more
openaire   +2 more sources

Novel GSK‐3 Inhibitor with Improved Cellular Activity.

ChemInform, 2004
AbstractFor Abstract see ChemInform Abstract in Full Text.
Andrew J, Peat, Dulce, Garrido, Joyce A, Boucheron, Stephanie L, Schweiker, Scott H, Dickerson, Jayme R, Wilson, Tony Y, Wang, Stephen A, Thomson   +7 more
openaire   +2 more sources

Cdc42 & GSK-3: signals at the crossroads

Nature Cell Biology, 2003
Cell polarity is regulated by independent pathways that are controlled by Wnt- or Cdc42-mediated signalling. Now, glycogen synthase kinase 3 (GSK-3), an established component of the Wnt pathway, is shown to interact with Par6–protein kinase C ζ (PKCζ), a complex that transduces Cdc42 signals.
Adrian, Harwood, Vania M M, Braga
openaire   +2 more sources

Effect of GSK-3 overactivation on neurofilament phosphorylation

Journal of Huazhong University of Science and Technology [Medical Sciences], 2005
In this study, we studied the effect of glycogen synthase kinase-3 (GSK-3) overactivation on neurofilament phosphorylation in cultured cells. After N2a cells were treated with the specific inhibitor (wortmannin) of phosphoinositol-3 kinase (PI-3K) or treated with wortmannin and the specific inhibitor (LiCl) of glycogen synthase kinase-3 (GSK-3), GSK-3 ...
Juan, Chen, Jie, Zhou, Youmei, Feng, Jianzhi, Wang   +3 more
openaire   +2 more sources

GSK-3 and the neurodevelopmental hypothesis of schizophrenia

European Neuropsychopharmacology, 2002
The Neurodevelopmental Hypothesis of schizophrenia suggests that interaction between genetic and environmental events occurring during critical early periods in neuronal growth may negatively influence the way by which nerve cells are laid down, differentiated and selectively culled by apoptosis.
Nitsan, Kozlovsky, R H, Belmaker, Galila, Agam   +2 more
openaire   +2 more sources

Substrate Competitive GSK-3 Inhibitors strategy and Implications

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
Glycogen synthase kinase-3 (GSK-3) is a highly conserved protein serine/threonine kinase ubiquitously distributed in eukaryotes as a constitutively active enzyme. Abnormally high GSK-3 activity has been implicated in several pathological disorders, including diabetes and neuron degenerative and affective disorders.
Hagit, Eldar-Finkelman, Avital, Licht-Murava, Shmuel, Pietrokovski, Miriam, Eisenstein   +3 more
openaire   +2 more sources

GSK-3 parameters in lymphocytes of schizophrenic patients

Psychiatry Research, 2002
Glycogen synthase kinase-3 (GSK-3) is a highly conserved serine/threonine protein kinase that is involved in the signal transduction cascades of multiple cellular processes. GSK-3 has two isoforms, designated alpha and beta. GSK-3beta protein levels and GSK-3 enzyme activity have been reported to be reduced by over 40% in postmortem frontal cortex of ...
Carmit, Nadri, Nitsan, Kozlovsky, Galila, Agam, Yuly, Bersudsky   +3 more
openaire   +2 more sources